Letters to the Editor

Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY
Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY
Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO
Hematology Department, University Hospital of Leon, Leon
Department of Hematology, Catholic University of Leuven, Leuven
Value, Evidence and Outcomes, GSK, Upper Providence, PA
Global Medical Affairs, GSK, Zug
Value, Evidence and Outcomes, GSK, Upper Providence, PA
Real World Study Delivery, GSK, Stevenage
Real World Data Strategy and Partnerships, Value, Evidence and Outcomes, GSK, Collegeville, PA
Groupe d’Analyse, Ltee., Montreal, Quebec
Groupe d’Analyse, Ltee., Montreal, Quebec
Groupe d’Analyse, Ltee., Montreal, Quebec
Analysis Group, Inc., Boston, MA
Groupe d’Analyse, Ltee., Montreal, Quebec
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli”, Universita degli Studi di Bologna, Bologna
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Haematologica Early view Oct 17, 2024 https://doi.org/10.3324/haematol.2024.285893